Total Payments
$115,087
2024 Payments
$9,419
Companies
22
Transactions
139
Medicare Patients
1,164
Medicare Billing
$217,560
Payment Breakdown by Category
Consulting$83,048 (72.2%)
Other$16,658 (14.5%)
Research$7,055 (6.1%)
Food & Beverage$4,453 (3.9%)
Travel$3,874 (3.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $83,048 | 37 | 72.2% |
| Honoraria | $8,553 | 5 | 7.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,105 | 4 | 7.0% |
| Unspecified | $7,055 | 22 | 6.1% |
| Food and Beverage | $4,453 | 48 | 3.9% |
| Travel and Lodging | $3,874 | 23 | 3.4% |
Payments by Type
General
$108,032
117 transactions
Research
$7,055
22 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma Global Development | $25,791 | 29 | $0 (2023) |
| PFIZER INC. | $16,893 | 13 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $15,766 | 20 | $0 (2024) |
| Dendreon Pharmaceuticals LLC | $10,383 | 14 | $0 (2020) |
| Astellas Pharma US Inc | $8,204 | 4 | $0 (2024) |
| AstraZeneca UK Limited | $7,770 | 7 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $7,699 | 9 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $6,687 | 8 | $0 (2019) |
| Progenics Pharmaceuticals, Inc. | $5,750 | 3 | $0 (2023) |
| AbbVie Inc. | $2,579 | 3 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $9,419 | 14 | AstraZeneca UK Limited ($3,222) |
| 2023 | $20,451 | 21 | PFIZER INC. ($8,805) |
| 2022 | $14,977 | 26 | Astellas Pharma Global Development ($5,129) |
| 2021 | $17,934 | 14 | PFIZER INC. ($7,765) |
| 2020 | $13,774 | 5 | Dendreon Pharmaceuticals LLC ($4,725) |
| 2019 | $9,772 | 21 | Merck Sharp & Dohme Corporation ($6,687) |
| 2018 | $11,863 | 18 | Bayer HealthCare Pharmaceuticals Inc. ($6,079) |
| 2017 | $16,897 | 20 | Astellas Pharma Global Development ($12,304) |
All Payment Transactions
139 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Janssen Scientific Affairs, LLC | ERLEADA (Drug) | Consulting Fee | Cash or cash equivalent | $2,300.00 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Janssen Scientific Affairs, LLC | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $149.12 | General |
| Category: Oncology | ||||||
| 10/28/2024 | Edap Technomed Inc | — | Food and Beverage | Cash or cash equivalent | $315.00 | General |
| 10/28/2024 | Edap Technomed Inc | — | Food and Beverage | Cash or cash equivalent | $315.00 | General |
| 10/28/2024 | Edap Technomed Inc | — | Food and Beverage | Cash or cash equivalent | $315.00 | General |
| 09/26/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $123.12 | General |
| 09/11/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Consulting Fee | Cash or cash equivalent | $1,875.00 | General |
| Category: Oncology | ||||||
| 06/27/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $149.70 | General |
| Category: Oncology | ||||||
| 06/11/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $1,611.00 | General |
| 06/11/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $21.76 | General |
| Category: SURGERY | ||||||
| 06/11/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $3.94 | General |
| Category: SURGERY | ||||||
| 05/03/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $500.00 | General |
| Category: SURGERY | ||||||
| 04/06/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $129.17 | General |
| Category: ONCOLOGY | ||||||
| 03/22/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $1,611.00 | General |
| 12/08/2023 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Consulting Fee | Cash or cash equivalent | $1,578.50 | General |
| Category: Oncology | ||||||
| 11/18/2023 | EMD Serono, Inc. | BAVENCIO (Drug) | Food and Beverage | Cash or cash equivalent | $146.78 | General |
| Category: Oncology | ||||||
| 11/01/2023 | Blue Earth Diagnostics Limited | POSLUMA (Drug) | Honoraria | Cash or cash equivalent | $787.50 | General |
| Category: Diagnostic Imaging | ||||||
| 10/17/2023 | PFIZER INC. | XTANDI (Drug), ORGOVYX | Food and Beverage | In-kind items and services | $63.03 | General |
| Category: ONCOLOGY | ||||||
| 10/02/2023 | Teleflex LLC | UROLIFT (Device) | Food and Beverage | In-kind items and services | $35.61 | General |
| Category: Interventional Urology | ||||||
| 09/09/2023 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $40.44 | General |
| Category: Oncology | ||||||
| 09/09/2023 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $19.03 | General |
| Category: Oncology | ||||||
| 08/14/2023 | PFIZER INC. | TALZENNA (Drug) | Travel and Lodging | Cash or cash equivalent | $450.60 | General |
| Category: ONCOLOGY | ||||||
| 07/05/2023 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Consulting Fee | Cash or cash equivalent | $1,435.00 | General |
| Category: Oncology | ||||||
| 06/30/2023 | Astellas Pharma Global Development | Xtandi (Drug) | — | Cash or cash equivalent | $331.70 | Research |
| Study: A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance (ENACT) • Category: Oncology | ||||||
| 05/23/2023 | PFIZER INC. | TALZENNA (Drug) | Consulting Fee | Cash or cash equivalent | $3,900.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance (ENACT) | Astellas Pharma Global Development | $4,077 | 15 |
| Use of multiple concurrent anticholinergics: Insights from the American Urological Association Quality (AQUA) Registry | Astellas Pharma Global Development | $2,977 | 7 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 288 | 302 | $514,836 | $51,443 |
| 2022 | 12 | 299 | 321 | $442,638 | $50,601 |
| 2021 | 12 | 307 | 320 | $526,790 | $55,595 |
| 2020 | 12 | 270 | 277 | $561,486 | $59,921 |
Total Patients
1,164
Total Services
1,220
Medicare Billing
$217,560
Procedure Codes
47
All Medicare Procedures & Services
47 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 55866 | Surgical removal of prostate and surrounding lymph nodes using an endoscope | Facility | 2023 | 23 | 23 | $226,826 | $24,317 | 10.7% |
| 38571 | Removal of lymph nodes of both sides of pelvis using an endoscope | Facility | 2023 | 21 | 21 | $88,956 | $6,207 | 7.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 29 | 29 | $31,465 | $4,285 | 13.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 45 | 51 | $29,427 | $3,713 | 12.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 27 | 29 | $22,417 | $3,404 | 15.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 34 | 34 | $29,478 | $3,132 | 10.6% |
| 55700 | Biopsy of prostate gland | Facility | 2023 | 24 | 24 | $41,280 | $2,624 | 6.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 25 | 27 | $10,611 | $1,472 | 13.9% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Facility | 2023 | 17 | 21 | $26,691 | $1,093 | 4.1% |
| 76942 | Ultrasonic guidance for needle placement | Facility | 2023 | 27 | 27 | $4,725 | $729.27 | 15.4% |
| 76872 | Ultrasound scan of pelvic region through rectum | Facility | 2023 | 16 | 16 | $2,960 | $466.88 | 15.8% |
| 55866 | Surgical removal of prostate and surrounding lymph nodes using an endoscope | Facility | 2022 | 20 | 20 | $197,240 | $25,310 | 12.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 50 | 57 | $32,889 | $4,506 | 13.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 29 | 29 | $31,465 | $4,391 | 14.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 29 | 29 | $22,417 | $3,422 | 15.3% |
| 38571 | Removal of lymph nodes of both sides of pelvis using an endoscope | Facility | 2022 | 12 | 12 | $50,832 | $3,362 | 6.6% |
| 55700 | Biopsy of prostate gland | Facility | 2022 | 24 | 25 | $43,000 | $2,738 | 6.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 22 | 22 | $19,074 | $2,176 | 11.4% |
| 76872 | Ultrasound scan of pelvic region through rectum | Facility | 2022 | 39 | 43 | $7,955 | $1,228 | 15.4% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Facility | 2022 | 13 | 17 | $21,607 | $1,021 | 4.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 16 | 18 | $7,074 | $1,012 | 14.3% |
| 76942 | Ultrasonic guidance for needle placement | Facility | 2022 | 30 | 34 | $5,950 | $920.85 | 15.5% |
| 76377 | 3d radiographic procedure with computerized image postprocessing | Facility | 2022 | 15 | 15 | $3,135 | $513.83 | 16.4% |
| 55866 | Surgical removal of prostate and surrounding lymph nodes using an endoscope | Facility | 2021 | 23 | 23 | $226,826 | $29,014 | 12.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 60 | 69 | $39,813 | $5,653 | 14.2% |
About Dr. Matthew Cooperberg, MD
Dr. Matthew Cooperberg, MD is a Urology healthcare provider based in San Francisco, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1841219326.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Matthew Cooperberg, MD has received a total of $115,087 in payments from pharmaceutical and medical device companies, with $9,419 received in 2024. These payments were reported across 139 transactions from 22 companies. The most common payment nature is "Consulting Fee" ($83,048).
As a Medicare-enrolled provider, Cooperberg has provided services to 1,164 Medicare beneficiaries, totaling 1,220 services with total Medicare billing of $217,560. Data is available for 4 years (2020–2023), covering 47 distinct procedure/service records.
Ad
Practice Information
- Specialty Urology
- Location San Francisco, CA
- Active Since 07/18/2006
- Last Updated 06/08/2010
- Taxonomy Code 208800000X
- Entity Type Individual
- NPI Number 1841219326
Products in Payments
- Xtandi (Drug) $22,009
- PROVENGE (Drug) $10,383
- TALZENNA (Drug) $8,541
- Nubeqa (Drug) $8,539
- Xofigo (Drug) $6,079
- PYLARIFY (Drug) $5,750
- XTANDI (Drug) $5,394
- ERLEADA (Drug) $4,812
- LYNPARZA (Drug) $4,548
- Myrbetriq (Drug) $2,569
- CABOMETYX (Drug) $1,980
- FOUNDATIONONE LIQUID CDX (Device) $1,750
- LUPRON DEPOT (Drug) $1,700
- Lupron Depot (Drug) $800.00
- POSLUMA (Drug) $787.50
- NO PRODUCT DISCUSSED (Drug) $707.91
- Da Vinci Surgical System (Device) $615.62
- MYRBETRIQ (Drug) $407.72
- Enzalutamide (Drug) $318.00
- BAVENCIO (Drug) $146.78
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Urology Doctors in San Francisco
Dr. Marshall Stoller, M.d, M.D
Urology — Payments: $340,565
Urology $340,565
Alvaro Santamaria, Md, MD
Urology — Payments: $55,685
Urology $55,685
Dr. Sima Porten, M.d, M.D
Urology — Payments: $53,279
Urology $53,279
Dr. Mang Chen, Md, MD
Urology — Payments: $49,472
Urology $49,472
Dr. Maxwell Meng, M.d, M.D
Urology — Payments: $41,583
Urology $41,583
Dr. Katsuto Shinohara, M.d, M.D
Urology — Payments: $36,583
Urology $36,583